Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 2043

Sort by

Sort Order Select

Journal Articles

Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR

Blood Adv (2025) 9 (21): 5460–5472.

https://doi.org/10.1182/bloodadvances.2025016141

Published: 2025

Includes: Supplemental data

Journal Articles

Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial

Raphael Steiner, Liana Nikolaenko, Ranjit Nair, Venkatraman Seshan, Swetha Kambhampati Thiruvengadam, Niloufer Khan, Jeremy S. Abramson, Steven Horwitz, Matthew Matasar, Colette Owens, Ildefonso Ismael Rodriguez Rivera, David J. Straus, Timothy S. Pardee, Sanjeev Luther, Sabrina Saboukoulou, Win Su Thet, Shreya Vemuri, Ariela Noy

Blood Adv (2025) 9 (21): 5556–5563.

https://doi.org/10.1182/bloodadvances.2025016168

Published: 2025

Includes: Supplemental data

Journal Articles

Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma

Blood Adv (2025) 9 (21): 5539–5545.

https://doi.org/10.1182/bloodadvances.2024015788

Published: 2025

Includes: Supplemental data

Journal Articles

Nivolumab in combination with R-CHOP for treatment-naïve diffuse large B-cell lymphoma: an evaluation of safety and efficacy

Blood Adv (2025) 9 (21): 5616–5625.

https://doi.org/10.1182/bloodadvances.2025016298

Published: 2025

Journal Articles

Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis

Blood Adv (2025) 9 (21): 5489–5500.

https://doi.org/10.1182/bloodadvances.2025016149

Published: 2025

Includes: Supplemental data

Journal Articles

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers

Teresa Caballero-Velázquez, Javier Delgado Serrano, Lucía López-Corral, Christelle Ferra-Coll, Clara Beatriz García-Calderón, David Valcárcel, Irene García-Cadenas, Estefanía Pérez López, María-José Jiménez Lorenzo, Francisco Manuel Martín-Domínguez, María de los Reyes Jiménez-León, Guillermo Orti, Virginia Escamilla Gómez, Cristina Blázquez-Goñi, Almudena Cabero Martínez, Henry Andrade Ruiz, Estefanía Menéndez-Pedregal, Fermín Sánchez-Guijo, José Antonio Pérez Simón

Blood Adv (2025) 9 (21): 5528–5538.

https://doi.org/10.1182/bloodadvances.2025016284

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary multicenter cohort

Henning Nilius, Ekaterina Sinitsa, Jan-Dirk Studt, Dimitrios A. Tsakiris, Andreas Greinacher, Adriana Mendez, Adrian Schmidt, Walter A. Wuillemin, Bernhard Gerber, Prakash Vishnu, Lukas Graf, Johanna A. Kremer Hovinga, Tamam Bakchoul, Michael Nagler

Blood Adv (2025) 9 (21): 5546–5555.

https://doi.org/10.1182/bloodadvances.2025016639

Published: 2025

Includes: Supplemental data

Journal Articles

ctDNA MRD after CAR-T

Salvatore Fiorenza, Mark R. Dowling

Blood Adv (2025) 9 (21): 5568–5570.

https://doi.org/10.1182/bloodadvances.2025017507

Published: 2025

Journal Articles

Racial and Clinical Determinants of Response in 2,304 r/r BCL Treated with Anti-CD19 CAR T-Cells in Clinical Trials

Soon Jye Kho, Sheila S Diamond, Penelope Lafeuille, Jonathan H Schatz, Francesco Maura, Jacob Aptekar, Frederick L Locke

Blood Adv bloodadvances.2025016361.

https://doi.org/10.1182/bloodadvances.2025016361

Published: 2025

Includes: Supplemental data

Journal Articles

The Right Glucarpidose?

Marise R Heerma van Voss, Maaike A Sikma, Frederike K Engels, Anita W Rijneveld, Marieke A Dijkman, Arjen Koppen, Martine E.D. Chamuleau, Imke H Bartelink

Blood Adv bloodadvances.2025017629.

https://doi.org/10.1182/bloodadvances.2025017629

Published: 2025

Journal Articles

Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2019

Zhiping Luo, Meng Li, Brian Primeaux, Rahul Shah, Ruitao Lin, Swaminathan P. Iyer, Loretta J. Nastoupil, Michael R Green, Jason R Westin, Christopher R Flowers, Dai Chihara

Blood Adv bloodadvances.2025017752.

https://doi.org/10.1182/bloodadvances.2025017752

Published: 2025

Includes: Supplemental data

Journal Articles

Decitabine-cedazuridine in patients with MDS and TP53 mutations

Samuel Urrutia, Koji Sasaki, Alex Bataller, Hagop M Kantarjian, Guillermo Montalban-Bravo, James McCloskey, Elizabeth A. Griffiths, Karen W.L. Yee, Amer M. Zeidan, Michael R Savona, Aram Oganesian, Yuri Sano, Harold Neal Keer, Guillermo Garcia-Manero

Blood Adv bloodadvances.2025017745.

https://doi.org/10.1182/bloodadvances.2025017745

Published: 2025

Includes: Supplemental data

Journal Articles

Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma

Chengcheng Fu, Wenming Chen, Zhen Cai, Lingzhi Yan, Huijuan Wang, Jingjing Shang, Yin Wu, Shuang Yan, Wen Gao, Xiaolan Shi, Xiaoyan Han, Fang Tang, Gaofeng Zheng, Yanling Wen, Xingxing Meng, Daijing Yuan, Huamao Wang, Zonghai Li

Blood Adv bloodadvances.2025017365.

https://doi.org/10.1182/bloodadvances.2025017365

Published: 2025

Includes: Supplemental data

Journal Articles

Reply to Gui and Hourigan

Mark J. Levis, Mehdi Hamadani, Yi-Bin Chen

Blood Adv bloodadvances.2025018319.

https://doi.org/10.1182/bloodadvances.2025018319

Published: 2025

Journal Articles

Too soon to reject immunoglobulin replacement in CLL

Stephen Opat, Ross Salvaris

Blood Adv (2025) 9 (20): 5380–5381.

https://doi.org/10.1182/bloodadvances.2025018034

Published: 2025

Journal Articles

Low bone mineral density and pain impact in adults with sickle cell disease

Oyebimpe Adesina, Jenna M Voutsinas, Qian Vicky Wu, Leyla Y Teos, Mehrad Rokni, Hande Nalbant, Lorenzo Nardo, Ted Wun, Babette S. Zemel

Blood Adv bloodadvances.2025015957.

https://doi.org/10.1182/bloodadvances.2025015957

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Vemircopan as Monotherapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

Austin G Kulasekararaj, Peter J Browett, Antonio Maria Risitano, Christopher J Patriquin, Mustafa Nuri Yenerel, Daniele Marceau, Fahri Sahin, Lorenzo Algarra, Masayo Ogawa, Ji Yu, Nicholas Cross, Rosario Notaro, Jong Wook Lee, Robert A. Brodsky

Blood Adv bloodadvances.2025017731.

https://doi.org/10.1182/bloodadvances.2025017731

Published: 2025

Includes: Supplemental data

Journal Articles

Childhood isolated C3d-positive AIHA: favorable prognosis but rare relapse or associated immunodeficiency

Blood Adv bloodadvances.2025017309.

https://doi.org/10.1182/bloodadvances.2025017309

Published: 2025

Includes: Supplemental data

Journal Articles

Survival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-up

Tatyana Gavrilova, Lori McIntyre, Stephanie L. Goff, James C. Yang, Danielle A. Natrakul, Steven A. Rosenberg, James N. Kochenderfer, Jennifer N. Brudno

Blood Adv (2025) 9 (20): 5362–5366.

https://doi.org/10.1182/bloodadvances.2025016504

Published: 2025

Includes: Supplemental data

Journal Articles

Olutasidenib: an Achilles’ heel for IDH1 -mutated MDS?

Laura Wiser, Curtis Lachowiez

Blood Adv (2025) 9 (20): 5341–5342.

https://doi.org/10.1182/bloodadvances.2025017582

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR

Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial

Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma

Nivolumab in combination with R-CHOP for treatment-naïve diffuse large B-cell lymphoma: an evaluation of safety and efficacy

Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers

Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary multicenter cohort

ctDNA MRD after CAR-T

Racial and Clinical Determinants of Response in 2,304 r/r BCL Treated with Anti-CD19 CAR T-Cells in Clinical Trials

The Right Glucarpidose?

Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2019

Decitabine-cedazuridine in patients with MDS and TP53 mutations

Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma

Reply to Gui and Hourigan

Too soon to reject immunoglobulin replacement in CLL

Low bone mineral density and pain impact in adults with sickle cell disease

Efficacy and Safety of Vemircopan as Monotherapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

Childhood isolated C3d-positive AIHA: favorable prognosis but rare relapse or associated immunodeficiency

Survival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-up

Olutasidenib: an Achilles’ heel for IDH1 -mutated MDS?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only